Protara Therapeutics, Inc. Income Statement
TARA|3 years of annual SEC 10-K data (FY2014-FY2016)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Protara Therapeutics, Inc. reported $3M in revenue and $3M in net loss for FY2016. Revenue has grown at a 0.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 |
|---|---|---|---|
| Revenue | $2.9M | $2.9M | $2.9M |
| SG&A Expense | $4.1M | $3.1M | $2.1M |
| R&D Expense | $6.4M | $4.0M | $5.9M |
| Operating Income | -$7.6M | -$7.1M | -$8.0M |
| Interest Expense | - | - | $861.0K |
| Income Tax | - | - | -$140.0K |
| Net Income | -$3.3M | -$7.9M | -$8.0M |
| EPS (Diluted) | -$3.16 | -$59.66 | -$61.16 |
| Shares Outstanding | 16.5M | 16.4M | 239.9K |
| Operating Margin | -257.1% | -241.6% | -271.2% |
| Profit Margin | -113.4% | -268.4% | -270.4% |